Sanochemia's Phase III Study Promises Advances in Prostate Cancer Detection with New MRI Contrast Agent Sanochemia announces significant results in its Phase III study of Ferumoxtran, a promising MRI contrast agent for prostate cancer detection.

Sanochemia's Phase III Study Promises Advances in Prostate Cancer Detection with New MRI Contrast Agent #Austria #Sanochemia #Ferumoxtran #MRI #Neufeld